Abstract: A treatment for pruritus is described that is based upon amylase. The amylases (?-, ?-, ?-amylase) are noted for the cleavage of the ?-glycosidic bonds of polysaccharides, yielding lower molecular weight carbohydrate/sugar fragments. It has now been found that ?-amylase is effective in the reduction of pruritus (itching) of affected tissue.

Abstract: The present invention relates to compositions comprising a construct comprising the A?1-6 peptide and a pharmaceutically acceptable adjuvant, for the treatment of patients suffering from dementia, in particular dementia of the Alzheimer's type.

Abstract: Provided herein are attenuated Salmonella bacteria for expressing autoantigen alone or in combination with an immunomodulator, as well as methods of using these bacteria to treat various autoimmune disorders.

Abstract: Compositions and methods for immunization against human breast cancer are disclosed. A breast cancer vaccine comprises an immunogenic polypeptide comprising human ?-lactalbumin.

Abstract: The invention provides a method of making a personalized neoplasia vaccine for a subject diagnosed as having a neoplasia, which includes identifying a plurality of mutations in the neoplasia, analyzing the plurality of mutations to identify a subset of at least five neo-antigenic mutations predicted to encode neo-antigenic peptides, the neo-antigenic mutations selected from the group consisting of missense mutations, neoORF mutations, and any combination thereof, and producing, based on the identified subset, a personalized neoplasia vaccine.

Abstract: According to the present invention, peptides having the amino acid sequence of SEQ ID NOs: 14, 21, 23, 27, 36, 46, 57, 60 and 62 were demonstrated to have cytotoxic T lymphocyte (CTL) inducibility. Therefore, the present invention provides a peptide having the amino acid sequence selected from among SEQ ID NOs: 14, 21, 23, 27, 36, 46, 57, 60 and 62. The peptide can include one, two, or several amino acid substitutions, deletions, insertions, or additions so long as its CTL inducibility is retained. Furthermore, the present invention provides pharmaceutical agents for the treatment and/or prophylaxis of cancers, and/or prevention of postoperative recurrence thereof, which contain any of these peptides. Pharmaceutical agents of this invention include vaccines.

Abstract: In some aspects, provided herein are methods and compositions for treating or preventing adverse cardiac events in a patient who has suffered an invasive pneumococcal infection or is at risk of such an infection. The compositions include fusion proteins comprising a CbpA polypeptide or active fragment or variant thereof and optionally a T cell epitope (TCE) and a third immunogenic polypeptide from a bacteria.

Abstract: Aqueous gel formulations, including an immune response modifier (IRM), such as those chosen from imidazoquinoline amines, tetrahydroimidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2-bridged imidazoquinoline amines, imidazonaphthyridine amines, imidazotetrahydronaphthyridine amines, oxazoloquinoline amines, thiazoloquinoline amines, oxazolopyridine amines, thiazolopyridine amines, oxazolonaphthyridine amines, thiazolonaphthyridine amines, pyrazolopyridine amines, pyrazoloquinoline amines, tetrahydropyrazoloquinoline amines, pyrazolonaphthyridine amines, tetrahydropyrazolonaphthyridine amines, and 1H-imidazo dimers fused to pyridine amines, quinoline amines, tetrahydroquinoline amines, naphthyridine amines, or tetrahydronaphthyridine amines, are provided. Methods of use and kits are also provided.

Abstract: The present invention relates to vectors useful in the treatment of disease through targeted delivery. In particular, the present invention relates to vectors useful in the treatment of disease associated with neuronal degeneration, such as amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA).

Abstract: The present invention relates to a method of treating patients suffering from cancers driven by deregulated Human Epidermal Growth Factor Receptor (HER/Human EGFR), wherein an irreversible tyrosine kinase inhibitor (TKI) is administered according to a continuous regimen based on an average daily dose in the range of 10 to 50 mg and the mAB is co-administered according to a dosing regimen ranging from an average weekly iv dose of 50 to 500 mg/m2 repeated thrice, twice or once a week, once in two weeks, once in three weeks or at least monthly to a patient in need of such treatment.

Abstract: A polymeric hydrogel pharmaceutical dosage form for drug delivery to a target site of a human or animal. The dosage form includes polyethylene-imine (PEI) and 1-vinylimidazole (1VA), the dosage form being electro-responsive in use. Also, methods of manufacturing the dosage form and methods of treating chronic pain utilizing the dosage form.

Abstract: Described are compositions of metal complexes that can be selectively activated by light when the metal complex is under acidic conditions, such as in a cancer cell. In some aspects, the metal complex can be utilized in a drug formulation with anti-cancer activity.

Abstract: The invention provides pharmaceutical compositions based on liquid vehicles whose density is substantially higher than that of aqueous physiological fluids. The compositions are useful as medicines in ophthalmology, in particular for the treatment of conditions affecting the posterior segment of an eye. They may be administered topically into the eye or in a minimally invasive manner by periocular injection. Preferred liquid carriers are selected from semifluorinated alkanes.

Abstract: Pharmaceutical concentrate formulations comprising 2-amino-I,3-propanediol compounds, analogs thereof and salts thereof, particularly 2-amino-2-[2-(4-octylphenyl)ethyl]-propane-1,3-diol or a pharmaceutically acceptable salt thereof in an organic solvent or semi-aqueous solvent and methods for administration of the undiluted and diluted concentrate are provided.

Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

Abstract: The present disclosure provides a stable protein composition containing a surfactant and having less than 400 subvisible particles of 10 microns or greater diameter per container, or less than 10,000 subvisible particles of 2 microns or greater per container. A method of manufacturing such a stable protein composition is disclosed, which includes a unit of operation that removes or decreases an esterase activity that degrades the surfactant. The unit of operation may be hydrophobic interaction chromatography or filtration, mixed mode chromatography, or the like.

Abstract: This invention harvests nanocomposite which enable targeted delivery of antibiotics. Biodegradable and biocompatible polymer such as diethylaminoethyl-cellulose (DEAE-Cellulose) are used in combination with iron, which contributes its magnetic characteristics to the nanocomposite. The nanoparticles produced could be used as carriers for releasing chloramphenicol at the targeted site for sustained release.

Abstract: The invention provides an ophthalmic product containing rebamipide, which has a transparency enough to be agreeable feeling on using it and has neutral so weakly acidic pH not to injury of the keratoconjunctiva of a patient suffering from dry eye. An aqueous suspension of crystalline rebamipide which has an improved transparency is provided by adding an aqueous solution of rebamipide dissolved by a base such as sodium hydroxide or an aqueous solution of a salt of rebamipide to an aqueous acidic solution such as hydrochloric acid containing at least one of the compounds selected from water-soluble polymers and surfactants, and mixing them.

Abstract: A substantially surface active agent tree composition which includes a hydrophobic solvent, and/or a petrolatm, a paraffin wax and/or a fatty alcohol, a fatty acid and/or a wax and/or shea butter, with and without a propellant. A substantially surface active agent free composition, further comprising, a tetracycline antibiotic, or a vitamin D derivative, or one or more other active agents. A method of treatment using a substantially surface active agent tree composition.

Abstract: Provided are methods relating to compositions that include a CDP-topoisomerase inhibitor, e.g., a CDP-camptothecin or camptothecin derivative conjugate, e.g., CRLX101.

Abstract: Derivatives of PSAs are synthesised, in which a reducing and/or non-reducing end terminal sialic acid unit is transformed into a N-hydroxysuccinimide (NHS) group. The derivatives may be reacted with substrates, for instance substrates containing amine or hydrazine groups, to form non-cross-linked/crosslinked polysialylated compounds. The substrates may, for instance, be therapeutically useful drugs, peptides or proteins or drug delivery systems.

Abstract: This specification is directed to nonlinear saccharide conjugates that comprise polysaccharides that are linked to at least two peptides that comprise T-cell epitopes and have no conformational B-cell epitopes where one of the peptides is linked to an internal saccharide so that the conjugates have a branched (i.e., nonlinear) structure. The specification also provides methods of manufacturing these conjugates, methods of formulating these conjugates in compositions for use as vaccines and methods of using the compositions to induce an immune response to the capsular saccharide. The specification also provides a new polyepitope carrier peptide comprising the PV1 epitope from polio virus. The new polyepitope carrier peptide can be used in both linear saccharide conjugates as well as the nonlinear saccharide conjugates.

Abstract: Compositions and methods for treating cancer in a subject are described herein. The composition includes modified nucleobases and nucleosides that are converted in the cell to nucleotides that are incorporated into growing DNA and result in termination of DNA elongation. The nucleobases and nucleotides are incorporated with a drug delivery system (DDS). The DDS includes ?-cyclodextrin. The nucleobases and nucleotides are conjugated to the ?-cyclodextrin by an acid labile linker that releases the nucleobases and nucleotides in the acidic environment of cancer cells. The DDS may also include a targeting ligand that targets the DDS/nucleobase or nucleotide conjugate to cancer cells. The DDS/nucleobase or nucleotide conjugate may self form into nanoparticles and may be administered to a subject with cancer in an amount effective to treat said cancer.

Abstract: The invention features compounds of formula V or XII: In one embodiment, the invention relates compounds and processes for conjugating ligand to oligonucleotide. The invention further relates to methods for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, cancers, allergies, autoimmune diseases, immunodeficiencies and immunosuppression.

Abstract: Using a novel water-soluble, active ester amide-containing functionalized controlled radical polymerization initiator, stimuli responsive polymers have been grown from the surface of a protein, exemplified by chymotrypsin or any protein having surface amino acids that will covalently bind to the active ester amide-containing functionalized initiator. It is shown that changes in temperature or pH can change the conformation of the polymer surrounding the enzyme, which in turn enabled the rational tailoring of enzyme activity and stability. This method has afforded an increase in the activity and stability of the enzyme by an order of magnitude at pH's where the enzyme is usually inactive or unstable. Multimodal temperature responsive protein-block copolymer conjugates are described.

Abstract: The invention provides processes for manufacturing cell-binding agent-cytotoxic agent conjugates of improved homogeneity comprising performing the modification reaction at a lower temperature. The inventive processes comprise contacting a cell-binding agent with a bifunctional crosslinking reagent at a temperature of about 15° C. or less to covalently attach a linker to the cell-binding agent and thereby prepare a mixture comprising cell-binding agents having linkers bound thereto.

Abstract: A process for preparing a porous solid with an outer surface modified by at least one polymer; the polymer being simultaneously synthetized in solution and grafted on the outer surface of the solid, includes contacting: a porous solid; and a polymer-precursor solution comprising an adhesion primer, and at least one polymerizable monomer; under conditions enabling the formation of radical entities.

Abstract: Recombinant vectors in which expression of one or more elements (e.g. genes required for viral replication, detectable imaging agents, therapeutic agents, etc.) is driven by a truncated CCN 1 cancer selective promoter (tCCN1-Prom) are provided, as are cells and transgenic animals that contain such vectors. The vectors are used in cancer therapy and/or diagnostics, and the transgenic mice are used to monitor cancer progression, e.g. in screening assays.

Abstract: Novel compositions, methods, systems and devices are disclosed which contain markers for definitive medication adherence monitoring for Active Pharmaceutical Ingredients (APIs) delivered topically, vaginally or rectally. This invention is useful in a wide range of contexts, including, but not limited to, clinical trial settings, home use settings, or other settings, where it is necessary to definitively confirm that a given patient has taken or been administered a given medication at the correct time and in the correct dosage via a topical, vaginal or rectal route of delivery. Specific formulations of markers are disclosed for inclusion in compositions for Active Pharmaceutical Ingredient (API) delivery, including but not limited to delivery of microbicidally active compounds such that on topical, vaginal or rectal delivery, said AEM is detected in the breath or an Exhaled Drug Emplacement Marker, EDEM, which is a metabolite of the AEM, is detected in the breath.

Abstract: Compounds and a method for imaging myocardial perfusion, including administering to a patient a compound linked to an imaging moiety, wherein the compound binds MC-1, and scanning the patient using diagnostic imaging. Kits including the compound or precursor compounds linked or not linked to an imaging moiety are also described.

Abstract: The present invention relates to a liquid pharmaceutical composition including a complex of formula (I), in which M is an ion of a paramagnetic metal and R1 to R3, X1 to X3 and K1 to K12 are such as defined in claim 1, said composition also including a calcium complex of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid. The invention also relates to the preparation method thereof and to an imaging method involving said composition.

Abstract: Provided are aromatic compounds, phospholipid-polymer-aromatic conjugates comprising the aromatic compounds, and liposome compositions including the phospholipid-polymer-aromatic conjugates. The liposomal compositions may be useful for imaging of Alzheimer's Disease, for example, imaging of the amyloid-? plaque deposits characteristic of Alzheimer's Disease.

Abstract: Alzheimer's disease is treated by attacking hyperactive microglia preferably before excessive beta amyloid is built up by administering tin-117m-DOTA annexin V. This compound in low radioactive doses selectively binds to the aged hyperactive microglia and emits a conversion electron which effectively induces apoptosis in the hyperactive microglia. A follow-up treatment of tin-annexin A1 can be administered to repair the blood brain barrier. The annexin A1 assists in the repair of the blood-brain barrier and the associated tin-117m will induce apoptosis in aged hyperactive microglia associated with the blood brain barrier.

Abstract: The present invention relates to radioimmunoconjugates that are capable of upregulating expression of one or more antigens. The upregulated antigens can be the antigens that are targeted by the radioimmunoconjugates or different antigens expressed on the same cells. The present invention also relates to methods of treating cancer and diseases and disorders of the immune system by utilizing this enhanced expression of antigens.

Abstract: Method for sterilizing a hydrogel composition include subjecting the composition to pulsed light comprising broadband spectrum radiation, the pulsed light being at a dose effective to sterilize the composition without causing significant change in rheology of the composition.

Abstract: A device is provided for the decontamination of hollow objects with a cavity such as caps, including: (i) a first exposure apparatus including at least a UV radiation source and a reflector oriented toward the cavity of the positioned objects, able to produce a direct exposure to UV radiations of surfaces inside the cavity, (ii) a second exposure apparatus including at least a UV radiation source placed on the opposite side relative to the cavity of the positioned objects, thes second exposure apparatus being able to expose surfaces inside the objects cavity to UV radiations by diffusion and/or transmission of UV radiations through the walls surrounding the objects cavity, and the first and second exposure apparatus cooperating for producing a global exposure to UV radiations of the surfaces inside the objects cavity. A method is also provided for the decontamination of hollow objects.

Abstract: An object sterilization system includes an enclosure having an access door with at least one ultraviolet emitting device supported within the enclosure. The ultraviolet emitting device(s) are for directing ultraviolet radiation on an object placed within the enclosure. A source of power is interfaced to each of the at least one ultraviolet emitting devices, operatively flowing current through each of the at least one ultraviolet emitting devices, thereby each of the at least one ultraviolet emitting device emits ultraviolet radiation for producing ozone and for sterilizing the object.

Abstract: Compositions comprising hydrophobically modified malodor control polymers and methods thereof are provided. In some embodiments, the composition comprises a malodor control polymer, a malodor counteractant comprising a perfume, an aqueous carrier, and a ph of about 6 to about 8. Such compositions may be used to reduce or neutralize malodors on surfaces or in the air.

Abstract: Soluble fibrous structures and more particularly soluble fibrous structures that contain one or more fibrous elements, such as filaments, having one or more fibrous element-forming materials and one or more active agents present within the fibrous elements, wherein the fibrous structure exhibits improved dissolution properties compared to known soluble fibrous structures, and method for making such improved fibrous structures are provided.

Abstract: Fragrance control is provided by articles of manufacture including various solid state fragrancing objects, methods of using such objects, and systems that employ one or more such objects. The solid state fragrancing object can be used to inconspicuously provide fragrance to a user in an environment by disposing the solid state fragrancing object in the environment and configuring the solid state fragrancing object as at least a portion of a fixture within the environment. The fragrancing object can be easy to manufacture, long lasting, provide fragrance that is consistently released over time, provide an indication to the user that the object needs to be replaced, and can hold a desired ratio of fragrance.

Abstract: The present invention provides a device for diffusing a compound comprising: a chamber arranged to store a compound, wherein the chamber includes an agitator member arranged to disturb the compound within the chamber to diffuse the compound into air within the chamber.

Abstract: Methods, processes and compositions are provided for improved wound dressings comprising an antimicrobial composition. The wound dressings maintain conformability and strength, as well as antimicrobial performance, upon use after storage.

Abstract: An absorbent article containing a nonwoven web that includes a plurality of polyolefin fibers is provided. The polyolefin fibers are formed by a thermoplastic composition containing a continuous phase that includes a polyolefin matrix polymer and nanoinclusion additive is provided. The nanoinclusion additive is dispersed within the continuous phase as discrete nano-scale phase domains. When drawn, the nano-scale phase domains are able to interact with the matrix in a unique manner to create a network of nanopores.

Abstract: The invention relates to a hot melt adhesive composition that, when used as an elastic attachment adhesive (EAA), provides elastic laminates having an initial creep performance of less than 25%. The composition comprises a selectively hydrogenated, high vinyl block copolymer having the structure SEBS or (SEB)nX amorphous polyolefin such as polyethylene, polypropylene, butylene homopolymers and copolymers, or a mixture of two or more of these, tackifier, and maleated polypropylene oligomer or maleated SEBS.

Abstract: A composition comprising honey and a super-absorbent material. A method of treating a lesion comprising applying a composition comprising honey and a super-absorbent material to the lesion. A method of manufacturing the composition of the invention, comprising: (a) providing at least one type of honey; (b) providing at least one super-absorbent material; and (c) combining the honey and super-absorbent material.

Abstract: According to an illustrative embodiment a method to promote healing of a wound is provided comprising contacting the wound with a biologically active composition comprising a lipoic acid derivative and gelatin. In another embodiment a topical composition is provided, which can be formulated as a homogenous mixture, such as a spray, mist, aerosol, lotion, cream, solution, oil, gel, ointment, paste, emulsion or suspension or applied on a carrier material, such as a bandage, gauze, foam, sponge, hydrogel, hydrocolloid, hydrofiber, occlusive dressing, adhesive composition or scaffold. Methods for producing such a topical composition and carrier material with the topical composition applied thereto are also disclosed.

Abstract: Suture-specific coatings having a number average molecular weight not exceeding 20 kDa, a melting temperature above 37° C., and heat of fusion exceeding 20 J/g, are formed of copolyesters of polycaprolactone or of ?-caprolactone and at least one cyclic monomer forming a segmented polyester chain initiated by a polyaxial crystalline organic compound or an amorphous polyaxial polymeric initiator and include from about 0.01 to about 10 weight percent of at least one molecularly dispersed bioactive agent.

Abstract: Compositions and methods for repair of tissue defects are disclosed. The compositions are prepared by entangling high molecular weight polycaprolactone polymer molecules with a polysaccharide such as hyaluronic acid by a dual solvent emulsion process to produce a porous flexible matrix which supports cell and tissue growth in vivo and ex vivo.

Abstract: The present invention relates to a minimally-invasive method for restoring a damaged or degenerated intevertebral disc at an early stage. The method comprises the step of administering an injectable in situ setting formulation in the nucleus pulposus of the damaged or degenerated disc of the patient. The formulation once injected combines with nucleus matters and host cells, and becomes viscous or gels in situ within the annulus fibrosus of the disc for increasing the thickness and volume of the damaged or degenerated disc. The formulation is retained within the disc for providing restoration of the damaged or degenerated disc.

Abstract: The present invention provides a preparation method for implantable medical biological material of animal origin comprising the following procedures: Pre-processing, and washing of animal tissue materials; inactivation of virus; decellularizing cell; sodium chloride processing; molding and packaging sterilization. Cell-free ECM materials of animal origin produced by this method can achieve the goal of completely removing cell components of animal origin and composition of DNA, and at the same time, the natural ECM composition, three-dimensional structure and active growth factor which can induce and promote tissue regeneration retain. By using this process, endotoxin, organic solvents and toxic solvent residue are thus omitted and products with different sizes, thickness and mechanical strength can be formed.